PharmaPoint: Osteoporosis - India Drug Forecast and Market Analysis to 2022

News provided by

Apr 10, 2013, 08:44 ET

NEW YORK, April 10, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Osteoporosis - India Drug Forecast and Market Analysis to 2022
http://www.reportlinker.com/p01158418/PharmaPoint-Osteoporosis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Summary

GlobalData has released its new Country report, "PharmaPoint: Osteoporosis - India Drug Forecast and Market Analysis to 2022". Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the 'gold-standard' bisphosphonates will lose patent protection by end-of-year 2013, flooding the marketplace with less expensive generic versions of these physician-preferred medications. Additionally, Eli Lilly's blockbuster Evista, the only available SERM in the US, will lose patent protection in 2014, flooding the market with yet more affordable generic options. Also during the forecast period covered by this report, osteoporosis drug development research will lead to the launches of a wave of novel anabolic drugs with greater efficacy and safety, causing a major market shift away from anti-resorptive drugs. The number of companies vying for patient share will shrink by as much as 50%, as established players exit the market or acquire smaller players. Lastly, the aging of the population in developed markets will result in a larger patient pool.

These changes in the osteoporosis market will be reflected in the slow growth during the forecast period, with the market growing from $6 billion to $8 billion in 2011 USD at a CAGR of 3%.

The recession will be caused by floods of generic products into the market. India has always had loose IP rights, requiring significant efficacy improvements in order for a drug to gain protection. However, as of 2012, India will start issuing compulsory licenses for Indian generics companies to violate IP and produce drugs prior to patent expiries. Therefore, GlobalData expects the Indian market to be dominated by generic products, and to lose significant value in the branded side of the drug market. For this reason, GlobalData did not project the pipeline products launching in the major markets because sales will likely be retarded by generic products.

Scope

- Overview of the Osteoporosis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in India including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in India from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting India Osteoporosis market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Osteoporosis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in India

Table of Contents

1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 9
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 15
3.1.3 Risk Factors 16
3.1.4 Quality of Life 16
3.2 Symptoms 17
4 Disease Management 18
4.1 Treatment Overview 18
4.1.1 Diagnosis and Referral 18
4.1.2 Treatment Guidelines 19
4.1.3 Disease Management 21
4.2 India 24
4.2.1 Diagnosis 24
4.2.2 Clinical Practice 24
5 Competitive Assessment 25
5.1 Overview 25
5.2 Strategic Competitor Assessment 25
5.3 Product Profiles – Major Brands 29
5.3.1 Actonel (risedronate sodium) 29
5.3.2 Evista (raloxifene hydrochloride) 32
5.3.3 Reclast (zolendronic acid) 36
5.3.4 Forteo (teriparatide) 39
5.3.5 Prolia (denosumab) 43
5.3.6 Protelos (strontium ranelate) 46
5.3.7 Miacalcin and Fortical (calcitonin-salmon) 49
5.3.8 Viviant/Conbriza (bazedoxifene) 53
5.3.9 Recalbon/Bonoteo (minodronic acid hydrate) 56
5.3.10 Alendronate sodium 58
5.3.11 Ibandronate 60
6 Opportunity and Unmet Need 61
6.1 Overview 61
6.2 Unmet Needs 62
6.2.1 Disease Awareness and Early Diagnosis 62
6.2.2 Patient Compliance 63
6.2.3 Efficacy 64
6.2.4 Safety 65
6.2.5 Treatment Cost 65
6.2.6 Earlier Intervention 66
6.3 Unmet Needs Gap Analysis 67
6.4 Opportunity 1: Dual-Action Therapies 69
6.5 Opportunity 2: Osteoporosis Prevention Therapies 69
6.6 Opportunity 3: Dosing and Administration 70
7 Pipeline Assessment 71
7.1 Overview 71
7.2 Promising Drugs in Clinical Development 72
7.2.1 Aprela (bazedoxifene and conjugated estrogens) 74
7.2.2 Romosozumab (AMG-785) 80
7.2.3 Odanacatib 86
7.2.4 BA-058 91
7.2.5 PTH(1-31)NH2 95
7.2.6 Ostora (recombinant salmon calcitonin) 100
8 Market Outlook 105
8.1 India 105
8.1.1 Forecast 105
8.1.2 Key Events 107
8.1.3 Divers and Barriers 108
9 Appendix 110
9.1 Bibliography 110
9.2 Abbreviations 116
9.3 Methodology 119
9.4 Forecasting Methodology 119
9.4.1 Diagnosed Osteoporosis Patients 119
9.4.2 Percent Drug-Treated Patients 119
9.4.3 Drugs Included in Each Therapeutic Class 120
9.4.4 General Pricing Assumptions 120
9.4.5 Individual Drug Assumptions 120
9.4.6 Generic Erosion 125
9.4.7 Pricing of Pipeline Agents 125
9.5 Physicians and Specialists Included in this Study 126
9.5.1 About the Authors 127
9.5.2 Global Head of Healthcare 128
9.6 About GlobalData 129
9.7 Contact Us 129
9.8 Disclaimer 129

List of Tables

Table 1: Etiology of Primary Osteoporosis 12
Table 2: Etiology of Secondary Osteoporosis 14
Table 3: Symptoms of Osteoporosis 17
Table 4: Diagnostic Tests for Osteoporosis 18
Table 5: T-Score Ranges for Determination of BMD 19
Table 6: Treatment Guidelines for Osteoporosis 20
Table 7: Most Prescribed Drugs for Osteoporosis by Therapeutic Class in the Global Markets, 2012 22
Table 8: Leading Treatments for Osteoporosis, 2012 28
Table 9: Product Profile – Actonel 30
Table 10: Actonel SWOT Analysis, 2012 31
Table 11: Product Profile – Evista 33
Table 12: Evista SWOT Analysis, 2012 34
Table 13: Product Profile – Reclast 37
Table 14: Reclast SWOT Analysis, 2012 38
Table 15: Product Profile – Forteo 40
Table 16: Mean Percent Change from Baseline in BMD with Forteo vs. Placebo in Postmenopausal Women with Osteoporosis 41
Table 17: Forteo SWOT Analysis, 2012 42
Table 18: Product Profile – Prolia 43
Table 19: Prolia SWOT Analysis, 2012 45
Table 20: Product Profile – Protelos 46
Table 21: Protelos SWOT Analysis, 2012 47
Table 22: Product Profile – Miacalcin and Fortical Nasal Spray 50
Table 23: Adverse Events with Miacalcin Nasal Spray 51
Table 24: Miacalcin and Fortical Nasal Spray SWOT Analysis, 2012 52
Table 25: Product Profile – Viviant/Conbriza 53
Table 26: Viviant/Conbriza SWOT Analysis, 2012 54
Table 27: Product Profile – Recalbon/Bonoteo 56
Table 28: Recalbon/Bonoteo SWOT Analysis, 2012 57
Table 29: Overall Unmet Needs – Current Level of Attainment 61
Table 30: Clinical Unmet Needs – Gap Analysis, 2012 67
Table 31: Osteoporosis – Pipeline, 2012 72
Table 32: Comparison of Therapeutic Classes in Development for Osteoporosis, 2012 72
Table 33: Product Profile – Aprela 75
Table 34: Aprela SWOT Analysis, 2012 79
Table 35: Product Profile – Romosozumab 81
Table 36: Romosozumab SWOT Analysis, 2012 85
Table 37: Product Profile – Odanacatib 86
Table 38: Odanacatib SWOT Analysis, 2012 90
Table 39: Product Profile – BA-058 91
Table 40: BA-058 SWOT Analysis, 2012 94
Table 41: Product Profile – PTH(1-31)NH2 96
Table 42: PTH(1-31)NH2 SWOT Analysis, 2012 98
Table 43: Product Profile – Ostora 101
Table 44: Ostora SWOT Analysis, 2012 103
Table 45: India Sales Forecasts ($m) for Osteoporosis, 2012-2022 106
Table 46: Key Events Impacting Sales for Osteoporosis in India, 2012–2022 107
Table 47: Osteoporosis Market – Drivers and Barriers in India, 2012–2022 108
Table 48: Number of High-Prescribing Physicians Surveyed 126